摘要
Abstract
Objective To evaluate the combined detection of serum CYFRA21-1,CEA,SCC,CA125 and CA19-9 levels in diagnosis of non-small cell lung cancer (NSCLC).Methods Serum specimens from 490 NSCLC patients,including 340 patients with adenocarcinoma,150 patients with squamous cell lung carcinoma (SCLC) and 133 patients with benign pulmonary disease were collected.Serum levels of CYFRA21-1,CEA,SCC,CA125 and CA19-9 were detected by ECLIA or CLIA.Results The serum levels of CYFRA21-1,CEA,SCC,CA125 and CA19-9 in patients with NSCLC were significantly higher than those with benign pulmonary disease (P＜0.05).The serum CEA level in lung adenocarcinoma patients were significantly higher than that of SCLC,while the CYFRA21-1 and SCC levels in SCLC patients were significantly higher than those of lung adenocarcinoma (P＜ 0.05).The serum levels of 5 markers in patients with stage Ⅲ and Ⅳ were significantly higher those in stage Ⅰ and Ⅱ (P＜0.05).For diagnosis of NSCLC the sensitivity of combined detection of five markers was 74.90％,the specificity was 84.96％,and the accuracy was 77.05％.Combined detection of CYFRA21-1 and CEA had better value for the diagnosis of lung adenocarcinoma (the sensitivity was 60.59％),while combined detection of CYFRA21-1 and SCC had better value for diagnosis of SCLC (the sensitivity was 88.67％).The AUC (0.745) of combination of CYFRA21-1 and CEA for lung adenocarcinoma was close to that of combined detection of 5 markers (0.771),and the AUC (0.942) of combination of CYFRA21-1 and SCC for SCLC was close to combined detection of five markers(0.946).Conclusion Serum CYFRA21-1,CEA,SCC,CA125 and CA19-9 are helpful for clinical diagnosis of non-small cell lung cancer.Serum CYFRA21-1 and CEA are the ideal combination for diagnosis of lung adenocarcinoma,while serum CYFRA21-1 and SCC are the ideal combination for diagnosis of lung squamous cell carcinomas.关键词
血清细胞角蛋白19片段/癌胚抗原/鳞状细胞癌抗原/糖链抗原125/糖链抗原19-9/非小细胞肺癌/病理亚型Key words
CYFRA21-1/CEA/SCC/CA125/CA19-9/NSCLC/Pathological subtype
